Shares of Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) dropped 0.6% during trading on Tuesday . The company traded as low as $0.2532 and last traded at $0.2532. Approximately 2,324 shares were traded during trading, a decline of 35% from the average session volume of 3,584 shares. The stock had previously closed at $0.2548.
Relief Therapeutics Stock Performance
The stock has a 50 day moving average price of $0.41 and a two-hundred day moving average price of $0.96.
Relief Therapeutics Company Profile
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Read More
- Five stocks we like better than Relief Therapeutics
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
